-
Something wrong with this record ?
Mitigation of Ionizing Radiation-Induced Gastrointestinal Damage by Insulin-Like Growth Factor-1 in Mice
J. Pejchal, A. Tichy, A. Kmochova, L. Fikejzlova, K. Kubelkova, M. Milanova, A. Lierova, A. Filipova, L. Muckova, J. Cizkova
Language English Country Switzerland
Document type Journal Article
NLK
Directory of Open Access Journals
from 2010
Free Medical Journals
from 2010
PubMed Central
from 2010
Europe PubMed Central
from 2010
Open Access Digital Library
from 2010-01-01
Open Access Digital Library
from 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2010
- Publication type
- Journal Article MeSH
Purpose: Insulin-like growth factor-1 (IGF-1) stimulates epithelial regeneration but may also induce life-threatening hypoglycemia. In our study, we first assessed its safety. Subsequently, we examined the effect of IGF-1 administered in different dose regimens on gastrointestinal damage induced by high doses of gamma radiation. Material and methods: First, fasting C57BL/6 mice were injected subcutaneously with IGF-1 at a single dose of 0, 0.2, 1, and 2 mg/kg to determine the maximum tolerated dose (MTD). The glycemic effect of MTD (1 mg/kg) was additionally tested in non-fasting animals. Subsequently, a survival experiment was performed. Animals were irradiated (60Co; 14, 14.5, or 15 Gy; shielded head), and IGF-1 was administered subcutaneously at 1 mg/kg 1, 24, and 48 h after irradiation. Simultaneously, mice were irradiated (60Co; 12, 14, or 15 Gy; shielded head), and IGF-1 was administered subcutaneously under the same regimen. Jejunum and lung damage were assessed 84 h after irradiation. Finally, we evaluated the effect of six different IGF-1 dosage regimens administered subcutaneously on gastrointestinal damage and peripheral blood changes in mice 6 days after irradiation (60Co; 12 and 14 Gy; shielded head). The regimens differed in the number of doses (one to five doses) and the onset of administration (starting at 1 [five regimens] or 24 h [one regimen] after irradiation). Results: MTD was established at 1 mg/kg. MTD mitigated lethality induced by 14 Gy and reduced jejunum and lung damage caused by 12 and 14 Gy. However, different dosing regimens showed different efficacy, with three and four doses (administered 1, 24, and 48 h and 1, 24, 48, and 72 h after irradiation, respectively) being the most effective. The three-dose regimens supported intestinal regeneration even if the administration started at 24 h after irradiation, but its potency decreased. Conclusion: IGF-1 seems promising in the mitigation of high-dose irradiation damage. However, the selected dosage regimen affects its efficacy.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22023813
- 003
- CZ-PrNML
- 005
- 20221031095154.0
- 007
- ta
- 008
- 221010s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fphar.2022.663855 $2 doi
- 035 __
- $a (PubMed)35847048
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Pejchal, Jaroslav $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Brno, Czechia
- 245 10
- $a Mitigation of Ionizing Radiation-Induced Gastrointestinal Damage by Insulin-Like Growth Factor-1 in Mice / $c J. Pejchal, A. Tichy, A. Kmochova, L. Fikejzlova, K. Kubelkova, M. Milanova, A. Lierova, A. Filipova, L. Muckova, J. Cizkova
- 520 9_
- $a Purpose: Insulin-like growth factor-1 (IGF-1) stimulates epithelial regeneration but may also induce life-threatening hypoglycemia. In our study, we first assessed its safety. Subsequently, we examined the effect of IGF-1 administered in different dose regimens on gastrointestinal damage induced by high doses of gamma radiation. Material and methods: First, fasting C57BL/6 mice were injected subcutaneously with IGF-1 at a single dose of 0, 0.2, 1, and 2 mg/kg to determine the maximum tolerated dose (MTD). The glycemic effect of MTD (1 mg/kg) was additionally tested in non-fasting animals. Subsequently, a survival experiment was performed. Animals were irradiated (60Co; 14, 14.5, or 15 Gy; shielded head), and IGF-1 was administered subcutaneously at 1 mg/kg 1, 24, and 48 h after irradiation. Simultaneously, mice were irradiated (60Co; 12, 14, or 15 Gy; shielded head), and IGF-1 was administered subcutaneously under the same regimen. Jejunum and lung damage were assessed 84 h after irradiation. Finally, we evaluated the effect of six different IGF-1 dosage regimens administered subcutaneously on gastrointestinal damage and peripheral blood changes in mice 6 days after irradiation (60Co; 12 and 14 Gy; shielded head). The regimens differed in the number of doses (one to five doses) and the onset of administration (starting at 1 [five regimens] or 24 h [one regimen] after irradiation). Results: MTD was established at 1 mg/kg. MTD mitigated lethality induced by 14 Gy and reduced jejunum and lung damage caused by 12 and 14 Gy. However, different dosing regimens showed different efficacy, with three and four doses (administered 1, 24, and 48 h and 1, 24, 48, and 72 h after irradiation, respectively) being the most effective. The three-dose regimens supported intestinal regeneration even if the administration started at 24 h after irradiation, but its potency decreased. Conclusion: IGF-1 seems promising in the mitigation of high-dose irradiation damage. However, the selected dosage regimen affects its efficacy.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Tichy, Ales $u Department of Radiobiology, Faculty of Military Health Sciences, University of Defence, Brno, Czechia
- 700 1_
- $a Kmochova, Adela $u Department of Radiobiology, Faculty of Military Health Sciences, University of Defence, Brno, Czechia
- 700 1_
- $a Fikejzlova, Lenka $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Brno, Czechia
- 700 1_
- $a Kubelkova, Klara $u Department of Molecular Pathology and Biology, Faculty of Military Health Sciences, University of Defence, Brno, Czechia
- 700 1_
- $a Milanova, Marcela $u Department of Radiobiology, Faculty of Military Health Sciences, University of Defence, Brno, Czechia
- 700 1_
- $a Lierova, Anna $u Department of Radiobiology, Faculty of Military Health Sciences, University of Defence, Brno, Czechia
- 700 1_
- $a Filipova, Alzbeta $u Department of Radiobiology, Faculty of Military Health Sciences, University of Defence, Brno, Czechia
- 700 1_
- $a Muckova, Lubica $u Department of Radiobiology, Faculty of Military Health Sciences, University of Defence, Brno, Czechia
- 700 1_
- $a Cizkova, Jana $u Department of Radiobiology, Faculty of Military Health Sciences, University of Defence, Brno, Czechia
- 773 0_
- $w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 13, č. - (2022), s. 663855
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35847048 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20221010 $b ABA008
- 991 __
- $a 20221031095152 $b ABA008
- 999 __
- $a ind $b bmc $g 1854033 $s 1175101
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 13 $c - $d 663855 $e 20220629 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
- LZP __
- $a Pubmed-20221010